WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou
Toxicology Facility as "Exemplary"
SHANGHAI, March 13, 2013
SHANGHAI, March 13, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading
pharmaceutical, biotechnology and medical device research and development
outsourcing company with operations in China and the United States, announced
today that its Suzhou toxicology facility had received full accreditation from
the Association for the Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) after an extensive on-site evaluation. The AAALAC
Committee on Accreditation commended the facility for "providing and
maintaining an exemplary program of animal care." This represents AAALAC's
highest level of commendation. The Suzhou facility first received
accreditation from AAALAC in February 2010.
AAALAC is a private, nonprofit organization that promotes the humane treatment
of animals in science through voluntary accreditation and assessment programs.
It evaluates all aspects of an animal care and use program, including
institutional policies, animal husbandry, veterinary care and the physical
plant. In its evaluations, it relies on widely accepted guidelines, such as
the Guide for the Care and Use of Laboratory Animals and other reference
resources, as well as its own position statements and Rules of Accreditation.
For more information, please contact:
Ronald Aldridge (for investors)
Aaron Shi (for the media)
SOURCE WuXi PharmaTech (Cayman) Inc.
Press spacebar to pause and continue. Press esc to stop.